

July 30, 2025

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001

BSE Scrip Code : 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Outcome of meeting of Board of Directors

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, enclosed please find herewith the Integrated Filing (Financials) containing the:

1. Unaudited standalone financial results for the quarter ended on June 30, 2025 accompanied by limited review report.
2. Unaudited consolidated financial results for the quarter ended on June 30, 2025 accompanied by limited review report.

Further, (i) The Statement on Deviation or Variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. and (ii) Format for disclosing outstanding default on loans and debt securities, are not applicable for the quarter ended June 30, 2025.

These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 4.16 p.m. and concluded at 5.24 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,
For J.B. Chemicals & Pharmaceuticals Ltd



Sandeep Phadnis
Vice President – Secretarial
& Company Secretary



**GOOD PEOPLE
for GOOD HEALTH**

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(₹ in lakhs)

Particulars	Quarter ended			Year ended
	30-06-2025	31-03-2025	30-06-2024	31-03-2025
	Unaudited	Unaudited (Refer note 7)	Unaudited	Audited
1. Revenue from operations	1,03,990	90,134	95,231	3,72,292
2. Other income	1,390	1,353	516	3,474
3. Total income (1+2)	1,05,380	91,487	95,747	3,75,766
4. Expenses				
a) Cost of materials consumed	24,083	18,897	25,167	82,004
b) Purchases of stock-in-trade	12,135	10,413	7,921	41,665
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3,115)	1,035	(819)	1,553
d) Employee benefits expense (Refer note 4)	18,204	16,612	15,667	64,679
e) Finance costs	66	93	432	912
f) Depreciation and amortisation expense	4,140	4,441	4,001	16,645
g) Other expenses	23,371	20,079	19,957	80,597
Total expenses	78,884	71,570	72,326	2,88,055
5. Profit before tax (3-4)	26,496	19,917	23,421	87,711
6. Tax expense				
a) Current tax	6,319	4,560	5,261	19,370
b) Current tax (credit) for earlier years	-	(201)	-	(201)
c) Deferred tax	390	578	837	3,288
Total tax expense	6,709	4,937	6,098	22,457
7. Net profit after tax (5-6)	19,787	14,980	17,323	65,254
8. Other comprehensive income/(loss)				
a) (i) Items that will not be reclassified to profit or loss	(125)	(13)	(124)	(592)
(ii) Income tax on items that will not be reclassified to profit or loss	31	3	31	149
b) (i) Items that will be reclassified to profit or loss	(28)	359	97	128
(ii) Income tax on items that will be reclassified to profit or loss	7	(90)	(24)	(32)
Total other comprehensive income/(loss) (net of tax)	(115)	259	(20)	(347)
9. Total comprehensive income after tax (7+8)	19,672	15,239	17,303	64,907
10. Paid-up equity share capital (face value ₹ 1/- each)	1,561	1,557	1,552	1,557
11. Other equity				3,36,163
12. Earnings per share (face value ₹ 1/- each)				
a) Basic (in ₹)	*12.70	*9.63	*11.16	42.00
b) Diluted (in ₹)	*12.48	*9.44	*10.94	41.16

*Not Annualised

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai - 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai - 400025, T:+91 22 24395200/5500

Notes:

1. The above standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on July 30, 2025. The statutory auditors have carried out a limited review of the standalone financial results of the Company for the quarter ended June 30, 2025. The results of the Company are available for investors at www.jbpharma.com, www.nseindia.com and www.bseindia.com.

2. These standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

3. On June 29, 2025, The Company has entered into a share purchase agreement ("SPA") with Torrent Pharmaceuticals Limited ("Acquirer") and Tau Investment Holdings Pte. Ltd. ("Tau"), promoter of the Company. Under the terms of the SPA, Torrent has agreed to acquire 7,44,81,519 (Seven Crore Forty-Four Lakh Eighty One Thousand Five Hundred and Nineteen) equity shares of the Company from Tau. Consequently, Torrent, as contemplated under the SPA and subject to receipt of the required statutory approvals and compliance with the SEBI (SAST) Regulations, will acquire control over the Company, and shall be classified as the 'promoter' of the Company in accordance with the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI (LODR) Regulations").

In accordance with Regulations 3(1) and 4 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI SAST Regulations"), Acquirer has made a public announcement for an open offer on 29 June, 2025 to the public shareholders of the Company for acquisition of equity shares.

Board of directors of the Acquirer and the Company, in the respective board meetings, have approved a scheme of amalgamation between the Acquirer and the Company under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 and other applicable law ("Scheme") pursuant to which, the Company will be amalgamated into the Acquirer as a going concern on receipt of requisite statutory approvals. In consideration for the merger, the Acquirer will issue and allot its equity shares to the shareholders of the Company (other than to the Acquirer itself), in a pre-agreed swap ratio of 51 (fifty-one) equity shares of Acquirer for every 100 (one hundred) equity shares held in the Company. The exchange ratio has been determined based on the valuation report issued by independent registered valuers and has been reviewed and recommended by the audit committees and board of directors of the respective companies.

4. The employee benefits expense during the quarters ended on June 30, 2025, March 31, 2025, June 30, 2024 and for the year ended March 31, 2025 includes charge of ₹ 1,381 lakhs, ₹ 1,352 lakhs, ₹ 1,088 lakhs and ₹ 5,348 lakhs respectively, towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.

5. The paid-up equity share capital of the Company stands increased by ₹ 3.82 lakhs upon allotment of 3,81,716 equity shares of ₹ 1 each pursuant to "ESOS Scheme" during the quarter ended June 30, 2025.

6. The Company has only one reportable business segment viz. "Pharmaceuticals".

7. The figures for the quarters ended March 31, 2025 are the balancing figures between the audited figures with respect of the full financial year upto March 31, 2025 and the unaudited published figures upto December 31, 2024 being the date of the end of the third quarter of the financial year which were subjected to limited review.

By order of the Board

For J.B. Chemicals & Pharmaceuticals Limited



Nikhil Chopra

Chief Executive Officer & Whole-time Director

Mumbai

July 30, 2025



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
J. B. CHEMICALS & PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **J. B. CHEMICALS & PHARMACEUTICALS LIMITED** ("the Company"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W 100018)



Rupen K. Bhatt
Partner

(Membership No. 046930)
UDIN: 25046930BMODSF3383



Place: Mumbai
Date: July 30, 2025



GOOD PEOPLE
for **GOOD HEALTH**

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(₹ in lakhs)

Particulars	Quarter ended			Year ended
	30-06-2025	31-03-2025	30-06-2024	31-03-2025
	Unaudited	Unaudited (Refer note 7)	Unaudited	Audited
1. Revenue from operations	1,09,394	94,948	1,00,440	3,91,799
2. Other income	1,455	1,448	589	3,832
3. Total income (1+2)	1,10,849	96,396	1,01,029	3,95,631
4. Expenses				
a) Cost of materials consumed	24,138	18,897	25,163	82,003
b) Purchases of stock-in-trade	14,941	13,596	10,101	49,695
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4,369)	(329)	(1,289)	(43)
d) Employee benefits expense (Refer note 4)	19,429	17,682	16,691	68,761
e) Finance costs	111	145	564	1,173
f) Depreciation and amortisation expense	4,270	4,644	4,078	17,104
g) Other expenses	25,168	22,458	21,737	88,199
Total expenses	83,688	77,093	77,045	3,06,892
5. Profit before tax (3-4)	27,161	19,303	23,984	88,739
6. Tax expense				
a) Current tax	6,559	4,799	5,447	20,242
b) Current tax (credit) for earlier years	-	(201)	-	(201)
c) Deferred tax	364	136	854	2,740
Total tax expense	6,923	4,734	6,301	22,781
7. Net profit after tax (5-6)	20,238	14,569	17,683	65,958
8. Other comprehensive income/(loss)				
a) (i) Items that will not be reclassified to profit or loss	(125)	(13)	(124)	(592)
(ii) Income tax on items that will not be reclassified to profit or loss	31	3	31	149
b) (i) Items that will be reclassified to profit or loss	515	1,486	830	1,356
(ii) Income tax on items that will be reclassified to profit or loss	9	(117)	(25)	(59)
Total other comprehensive income/(loss) (net of tax)	430	1,359	712	854
9. Total comprehensive income after tax (7+8)	20,668	15,928	18,395	66,812
10. Net profit after tax for the period/year attributable to:				
a) Owners of the company	20,238	14,569	17,683	65,958
b) Non-controlling interest	-	-	-	-
11. Other comprehensive income for the period/year attributable to:				
a) Owners of the company	430	1,359	712	854
b) Non-controlling interest	-	-	-	-
12. Total comprehensive income attributable to :				
a) Owners of the company	20,668	15,928	18,395	66,812
b) Non-controlling interest	-	-	-	-
13. Paid-up equity share capital (face value ₹ 1/- each)	1,561	1,557	1,552	1,557
14. Other equity				3,41,775
15. Earnings per share (face value ₹ 1/- each)				
a) Basic (in ₹)	*12.99	*9.36	*11.39	42.45
b) Diluted (in ₹)	*12.75	*9.17	*11.19	41.56
*Not Annualised				

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai - 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai - 400025, T:+91 22 24395200/5500

Notes:

1. The above consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on July 30, 2025. The statutory auditors have carried out a limited review of the consolidated financial results of the Company for the quarter ended June 30, 2025. The results of the Company are available for investors at www.jbpharma.com, www.nseindia.com and www.bseindia.com.

2. These consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The consolidated financial results of the Holding Company, its wholly owned subsidiaries and step-down subsidiaries ('the Group') have been prepared by applying Ind AS 110 on Consolidated Financial Statements.

3. On June 29, 2025, The Company has entered into a share purchase agreement ("SPA") with Torrent Pharmaceuticals Limited ("Acquirer") and Tau Investment Holdings Pte. Ltd. ("Tau"), promoter of the Company. Under the terms of the SPA, Torrent has agreed to acquire 7,44,81,519 (Seven Crore Forty-Four Lakh Eighty-One Thousand Five Hundred and Nineteen) equity shares of the Company from Tau. Consequently, Torrent, as contemplated under the SPA and subject to receipt of the required statutory approvals and compliance with the SEBI (SAST) Regulations, will acquire control over the Company, and shall be classified as the 'promoter' of the Company in accordance with the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI (LODR) Regulations").

In accordance with Regulations 3(1) and 4 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI SAST Regulations"), Acquirer has made a public announcement for an open offer on 29 June, 2025 to the public shareholders of the Company for acquisition of equity shares.

Board of directors of the Acquirer and the Company, in the respective board meetings, have approved a scheme of amalgamation between the Acquirer and the Company under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 and other applicable law ("Scheme") pursuant to which, the Company will be amalgamated into the Acquirer as a going concern on receipt of requisite statutory approvals. In consideration for the merger, the Acquirer will issue and allot its equity shares to the shareholders of the Company (other than to the Acquirer itself), in a pre-agreed swap ratio of 51 (fifty-one) equity shares of Acquirer for every 100 (one hundred) equity shares held in the Company. The exchange ratio has been determined based on the valuation report issued by independent registered valuers and has been reviewed and recommended by the audit committees and board of directors of the respective companies.

4. The employee benefits expense during the quarters ended on June 30, 2025, March 31, 2025, June 30, 2024 and for the year ended March 31, 2025 includes charge of ₹ 1,410 lakhs, ₹ 1,387 lakhs, ₹ 1,124 lakhs and ₹ 5,490 lakhs respectively, towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.

5. The paid-up equity share capital of the Holding company stands increased by ₹ 3.82 lakhs upon allotment of 3,81,716 equity shares of ₹ 1 each pursuant to "ESOS Scheme" during the quarter ended June 30, 2025.

6. The Group has only one reportable business segment viz., "Pharmaceuticals".

7. The figures for the quarters ended March 31, 2025 are the balancing figures between the audited figures with respect of the full financial year upto March 31, 2025 and the unaudited published figures upto December 31, 2024 being the date of the end of the third quarter of the financial year which were subjected to limited review.

By order of the Board
For J.B. Chemicals & Pharmaceuticals Limited

Mumbai
July 30, 2025


Nikhil Chopra
Chief Executive Officer & Whole-time Director



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF J. B. CHEMICALS & PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **J. B. CHEMICALS & PHARMACEUTICALS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent – J. B. Chemicals & Pharmaceuticals Limited

Direct Subsidiaries – OOO Unique Pharmaceuticals Limited; and
Unique Pharmaceuticals Limited FZE

Step down Subsidiary – Biotech Laboratories (Pty.) Ltd.; and
JBCPL Philippines Inc.



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of one subsidiary included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. 6,059.03 Lakhs for the quarter ended June 30, 2025, total net profit after tax of Rs. 476.01 Lakhs for the quarter ended June 30, 2025 and other comprehensive income of Rs. (4.56) Lakhs for the quarter ended June 30, 2025, as considered in the Statement. These interim financial information has been reviewed by another auditor whose report has been furnished to us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results include the interim financial information of three subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect, total revenue of Rs. 2,464.94 Lakhs for the quarter ended June 30, 2025, total (loss) after tax of Rs. (196.59) Lakhs for the quarter ended June 30, 2025 and other comprehensive income of Rs. Nil for the quarter ended June 30, 2025, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Rupen K. Bhatt
Partner

(Membership No. 04630)
UDIN: 25046930BMODS46686

Place: Mumbai
Date: July 30, 2025